Sutro Biopharma, Inc.
STRO
$30.52
$0.973.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -16.53% | -21.35% | 13.77% | 147.98% | 33.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.53% | -21.35% | 13.77% | 147.98% | 33.76% |
| Cost of Revenue | -64.93% | -48.42% | -35.83% | -38.21% | -95.98% |
| Gross Profit | -9.22% | 55.55% | 43.72% | 170.00% | 134.45% |
| SG&A Expenses | -42.86% | -4.08% | -39.01% | -16.39% | 4.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.96% | -43.42% | -36.43% | -34.58% | -6.79% |
| Operating Income | 37.62% | 48.42% | 42.72% | 130.97% | 16.12% |
| Income Before Tax | 49.32% | 33.16% | -16.54% | 76.01% | -30.49% |
| Income Tax Expenses | -314.29% | -103.48% | -- | -325.00% | -- |
| Earnings from Continuing Operations | 49.34% | 35.45% | -16.54% | 76.05% | -30.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.34% | 35.45% | -16.54% | 76.05% | -30.50% |
| EBIT | 37.62% | 48.42% | 42.72% | 130.97% | 16.12% |
| EBITDA | 37.82% | 49.47% | 44.04% | 136.20% | 16.89% |
| EPS Basic | 67.61% | 37.42% | -12.66% | 77.00% | 4.11% |
| Normalized Basic EPS | 55.23% | 41.25% | 36.92% | 112.55% | 34.80% |
| EPS Diluted | 67.61% | 37.42% | -12.66% | 77.00% | 4.11% |
| Normalized Diluted EPS | 55.23% | 41.25% | 36.92% | 112.55% | 34.80% |
| Average Basic Shares Outstanding | 56.41% | 3.16% | 3.44% | 4.13% | 36.10% |
| Average Diluted Shares Outstanding | 56.41% | 3.16% | 3.44% | 4.13% | 36.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |